Dan Savyckyj (Observer)
Director, Strategy and Business Development, Bristol-Myers Squibb
Dan Savyckyj is a director in the strategy and business development group at Bristol-Myers Squibb (BMS). In addition to other business development responsibilities, Mr. Savyckyj is mainly dedicated to BMS’ equity group, where he helps manage BMS’ direct equity portfolio and limited partnership investments. More recently, he led BMS’ investments in Transition Bio, Metagenomi, Clade Therapeutics and Outpace Bio. In addition to serving as board observer for Autobahn, Mr. Savyckyj also serves on the Droia Ventures (GD) Investment Committee and on the Limited Partner Advisory Committee (LPAC) for the Dementia Discovery Fund-2, an SV Health Investors fund. Prior to BMS, Mr. Savyckyj worked at Glaxo SmithKline and Novartis in various business development roles. Prior to his pharmaceutical industry career, he was a buyside equity fund manager at Evergreen Investments, an analyst at Baring Asset Management and worked as an analyst at the IFC-World Bank. Mr. Savyckyj holds a BA from the University of Pennsylvania, an MBA from Georgetown University and completed didactic studies and clinical rounds at Jefferson Medical College.